NeoGenomics, Inc. (NEO)
| Market Cap | 805.43M |
| Revenue (ttm) | 689.19M |
| Net Income (ttm) | -104.04M |
| Shares Out | 129.18M |
| EPS (ttm) | -0.82 |
| PE Ratio | n/a |
| Forward PE | 47.99 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,831,520 |
| Open | 6.07 |
| Previous Close | 6.08 |
| Day's Range | 6.05 - 6.34 |
| 52-Week Range | 4.72 - 19.12 |
| Beta | 1.54 |
| Analysts | Buy |
| Price Target | 12.00 (+92.46%) |
| Earnings Date | Jul 29, 2025 |
About NEO
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on d... [Read more]
Financial Performance
In 2024, NeoGenomics's revenue was $660.57 million, an increase of 11.65% compared to the previous year's $591.64 million. Losses were -$78.73 million, -10.51% less than in 2023.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for NEO stock is "Buy." The 12-month stock price target is $12.0, which is an increase of 92.46% from the latest price.
News
Neo Performance Materials Inc. (NOPMF) Q2 2025 Earnings Conference Call Transcript
Neo Performance Materials Inc. (OTCPK:NOPMF) Q2 2025 Earnings Conference August 12, 2025 10:00 AM ET Company Participants Irina Kuznetsova - Corporate Participant Jonathan Baksh - Executive VP & CFO R...
NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched the NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test, expanding the company's PanTracer portfolio.
NeoGenomics, Inc. (NEO) Q2 2025 Earnings Call Transcript
NeoGenomics, Inc. (NASDAQ:NEO) Q2 2025 Earnings Conference Call July 29, 2025 8:30 AM ET Company Participants Anthony P. Zook - CEO & Director Jeffrey S.
NeoGenomics Reports Second Quarter 2025 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its second-quarter results for the period ended June 30, 2025.
NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025.
NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched PanTracer™ Tissue, a next-generation solid tumor profiling assay, with the option to add HRD testing.
NeoGenomics Appoints Dr. Marjorie Green to Board of Directors
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025.
NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will debut its PanTracer Family and unveil the Paletrra platform at ASCO 2025, advancing precision oncology diagnostics.
NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the commercial launch of c-MET CDx for NSCLC, its c-MET companion diagnostic immunohistochemistry (IHC) assay.
NeoGenomics to Participate in Upcoming June Investor Conferences
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the William Blair Growth Stock Conference in Chicago and the Jefferies Global Healthcare Conference in New York.
NeoGenomics Pays Off 1.25% Convertible Senior Notes
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics has paid off in full the remaining $201.25 million in principal amount outstanding of its 1.25% Convertible Senior Notes.
NeoGenomics Q1 Earnings: The Stock Price Drop Is A Gift (Rating Upgrade)
NeoGenomics' recent 32.23% stock price decline post-Q1 earnings miss is seen as a buying opportunity due to overreaction and long-term growth potential. Despite a slight revenue miss, the company's lo...
NeoGenomics, Inc (NEO) Q1 2025 Earnings Call Transcript
NeoGenomics, Inc (NASDAQ:NEO) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Kendra Sweeney - Vice President, Investor Relations and ESG Tony Zook - Chief Executive O...
NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform
FORT MYERS, Fla. and FREMONT, Calif.
NeoGenomics Reports First Quarter 2025 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its first-quarter results for the period ended March 31, 2025.
NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced analytical validation of its PanTracer LBx™ assay, to be presented with five other abstracts at the AACR Annual Meeting 2025.
NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its first quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, April 29, 2025.
NeoGenomics Completes Acquisition of Pathline
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics has completed its previously announced acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey.
Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced that Tony Zook has officially assumed the role of Chief Executive Officer.
NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey.
NeoGenomics: Decent Fundamentals, But Still Overvalued
NeoGenomics is rated a Hold due to the intrinsic value being lower than the current price, and the company's negative net income and FCF. Despite revenue growth and increasing clinical volume, NeoGeno...
NeoGenomics to Participate in Upcoming Investor Conferences
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in several upcoming investor conferences.
NeoGenomics, Inc (NEO) Q4 2024 Earnings Call Transcript
NeoGenomics, Inc (NASDAQ:NEO) Q4 2024 Earnings Conference Call February 18, 2025 8:30 AM ET Company Participants Kendra Sweeney - Vice President, Investor Relations and ESG Chris Smith - Chief Execut...
NeoGenomics Reports Fourth Quarter and Full Year 2024 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its fourth-quarter and full year results for the period ended December 31, 2024.
NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its fourth quarter and full year 2024 financial results prior to the open of the U.S. financial markets on Feb. 18, 2025.